# Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

Source: https://onco.cc/trials/nct03697707/  
OnCo record `nct03697707` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vididencel run by Mendus, of unknown status on the registry.

## Summary

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia is a phase 2 interventional study registered as NCT03697707 by Mendus, with 20 participants planned, started 2018-10-15. Conditions recorded: Acute Myeloid Leukemia in Remission. Interventions recorded: DCP-001.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03697707
- Phase: 2
- Setting: An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD
- Sponsor: Mendus
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT03697707: https://clinicaltrials.gov/study/NCT03697707

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Vididencel](https://onco.cc/drugs/vididencel/)
- companies: [Mendus](https://onco.cc/companies/mendus/)

---
JSON: https://onco.cc/api/v1/entities/nct03697707.json